Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
University of Pennsylvania · Hospital of the University of Pennsylvania · +9 more institutions
Indexed incrossrefpubmed
Abstract
Objectives
The objective of this study was to contribute long-term safety data for infliximab and other therapies in Crohn's disease (CD).
Methods
We prospectively evaluated CD patients enrolled in the large, observational Crohn's Therapy, Resource, Evaluation, and Assessment Tool registry, established to compare infliximab safety with conventional nonbiological medications in CD.
Citation impact
789
total citations
- FWCI
- 38.63
- Percentile
- 100%
- References
- 29
Citations per year
Authors
9- GRGary R. LichtensteinCorresponding
University of Pennsylvania, Hospital of the University of Pennsylvania
- BGBrian G. Feagan
Western University, Robarts Clinical Trials
- RDRussell D. Cohen
University of Chicago Medical Center
- BSBruce Salzberg
Atlanta Gastroenterology Associates
- RHRobert H. Diamond
Janssen (United States)
Topics & keywords
Topics
Keywords
- Medicine
- Infliximab
- Internal medicine
- Hazard ratio
- Crohn's disease
- Prednisone
- Confidence interval
- Inflammatory bowel disease
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.